LOARGYS is the first and only therapy proven to lower arginine in patients 2 years of age and older living with ARG1-D -- ARG1-D is an ultra-rare, debilitating, and progressive metabolic disease ...

Pegzilarginase is an enzyme replacement therapy that provides an exogenous source of the deficient human arginase 1 enzyme to reduce blood arginine levels.

A Chiesi Farmaceutici drug for a rare enzyme deficiency is now approved by the FDA, making it the first U.S. treatment for a disorder that leads to a range of cognitive and muscle problems. The ...

For much of nutrition science history, trace minerals were discussed almost exclusively in the context of deficiency diseases ...

In certain groups of men, glucose-6-phosphate dehydrogenase (G6PD) deficiency was linked with an increased likelihood of severe COVID-19, a Veterans Affairs cohort study found. In Black men under 65, ...

To protect this child from the same genetic disease that killed two older siblings, treating her as soon as she was born might only work so well, the doctors knew. So they dialed back the therapeutic ...

Acid lipase deficiency is a rare genetic disorder that affects the lysosomal acid lipase (LAL) enzyme. This enzyme is crucial for managing fat and cholesterol levels throughout the body. LAL helps ...

Immedica Pharma today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Loargys® (pegzilarginase-nbln), an arginine specific enzyme indicated for the ...